View Older Stories View More Recent Stories

Mar 22, 2023 05:08PM Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline Updates
Mar 15, 2023 07:30AM Context Therapeutics Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023
Mar 15, 2023 07:30AM Context Therapeutics Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023
Feb 6, 2023 07:37AM Context Therapeutics (CNTX) Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer
Feb 6, 2023 07:30AM Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer
Feb 6, 2023 07:30AM Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer
Jan 31, 2023 07:30AM Context's (CNTX) Partner Stemline Therapeutics Announces FDA Approval of ORSERDU
Jan 31, 2023 07:30AM Context Therapeutics’ Clinical Partner Stemline Therapeutics, a Subsidiary of Menarini Group Receives FDA Approval of ORSERDU™ (elacestrant) in ER+, HER2-, ESR1-mutated Breast Cancer
Jan 31, 2023 07:30AM Context Therapeutics’ Clinical Partner Stemline Therapeutics, a Subsidiary of Menarini Group Receives FDA Approval of ORSERDU™ (elacestrant) in ER+, HER2-, ESR1-mutated Breast Cancer
Jan 9, 2023 07:33AM Context (CNTX) and Lonza Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive Cancers
Jan 9, 2023 07:31AM Context Therapeutics (CNTX), Lonza Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive Cancers
Jan 9, 2023 07:30AM Context Therapeutics and Lonza Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive Cancers
Jan 9, 2023 07:30AM Context Therapeutics and Lonza Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive Cancers
Jan 4, 2023 07:30AM Context Therapeutics® Highlights 2023 Corporate Priorities and Pipeline Milestones
Jan 4, 2023 07:30AM Context Therapeutics® Highlights 2023 Corporate Priorities and Pipeline Milestones
Dec 8, 2022 07:30AM Context Therapeutics (CNTX) Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer
Dec 8, 2022 07:30AM Context Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer
Dec 8, 2022 07:30AM Context Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer
Nov 29, 2022 07:31AM Context Therapeutics (CNTX) Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Solid Tumors
Nov 29, 2022 07:30AM Context Therapeutics® Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Solid Tumors
Nov 29, 2022 07:30AM Context Therapeutics® Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Solid Tumors
Nov 21, 2022 09:14AM Context Therapeutics (CNTX) Provides ONA-XR Clinical Updates
Nov 21, 2022 09:11AM Context Therapeutics® Announces Clinical Updates on ONA-XR to be Presented at 2022 San Antonio Breast Cancer Symposium
Nov 21, 2022 09:11AM Context Therapeutics® Announces Clinical Updates on ONA-XR to be Presented at 2022 San Antonio Breast Cancer Symposium
Nov 9, 2022 04:14PM Context Therapeutics® Reports Third Quarter 2022 Operating and Financial Results
Nov 9, 2022 04:14PM Context Therapeutics® Reports Third Quarter 2022 Operating and Financial Results
Oct 20, 2022 07:30AM Context Therapeutics to Participate in the ThinkEquity Conference
Sep 27, 2022 07:30AM Context Therapeutics® Amends Cash Guidance, Extends Runway into Q1 2024
Sep 27, 2022 07:30AM Context Therapeutics® Amends Cash Guidance, Extends Runway into Q1 2024
Sep 6, 2022 07:30AM Context Therapeutics® to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
Sep 6, 2022 07:30AM Context Therapeutics® to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
Aug 11, 2022 04:01PM Context Therapeutics® Reports Second Quarter 2022 Operating and Financial Results
Aug 11, 2022 04:01PM Context Therapeutics® Reports Second Quarter 2022 Operating and Financial Results
View More Recent Stories View Older Stories